1stOncology™: Cancer Intelligence Service – Page 308 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Non-consolidated Financial Results for the Nine Months Ended September 30, 2025

On November 7, 2025 Oncolys BioPharma reported Non-consolidated Financial Results for the Nine Months Ended September 30, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

(Press release, Oncolys BioPharma, NOV 7, 2025, View Source [SID1234661725])

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

On November 7, 2025 Cellectis reported Third Quarter 2025 Financial Results and Provides Business Update.

(Press release, Cellectis, NOV 7, 2025, View Source [SID1234661700])

Trained Therapeutix Discovery Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

On November 7, 2025 Trained Therapeutix Discovery, Inc., a biotech company training immunity at its origin with nanomedicines, reported preclinical data on RIDE-001, a nanomedicine designed to program myeloid progenitor cells for an anticancer innate immune response, were presented in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting. The data demonstrated that RIDE-001 effectively induced trained immunity in vitro in primary human immune cells, induced anti-tumor immunity in mouse tumor models of melanoma and colorectal cancer, and safely induced innate immune responses in rats and non-human primates. RIDE-001 showed therapeutic activity against solid tumors as a single agent, and it also exhibited synergy in combination with immune checkpoint inhibition.

"Myeloid cells can promote cancer by suppressing anti-tumor immune responses, enhancing tumor angiogenesis and facilitating metastasis, but due to their plasticity in the tumor microenvironment, they have been considered an unattractive therapeutic target," said Willem Mulder, PhD, Chief Scientific Officer of Trained Therapeutix Discovery. "Our approach with RIDE-001 is a breakthrough in immune-oncology, as it targets myeloid progenitor cells before they differentiate into immune cells. By programing myeloid cells at their naissance, we can deploy the power of the innate immune response against cancer. Based on these promising data demonstrating consistent myeloid cell training and antitumor activity across species, in addition to RIDE-001’s favorable safety profile, we have initiated GMP manufacturing in anticipation of the first clinical studies in patients with solid tumors."

RIDE-001 was developed using Trained Therapeutix Discovery’s proprietary ApoA1-based nanomedicines platform to target the bone marrow where it activates the intracellular pattern recognition receptor NOD2. This triggers epigenetic changes in myeloid progenitor cells, inducing the production of trained myeloid cells to generate durable, anti-tumor responses.

RIDE-001 preclinical data showed:

A dose-dependent rise in NOD2 activation;
Trained immunity as assessed by peripheral blood mononuclear cells (PBMCs);
Trained myeloid cells in rats demonstrating a shift in monocyte phenotype and increased blood neutrophil counts;
Trained myeloid cells in non-human primates with a consistent increase in intermediate monocytes in both males and females following each administered dose;
Single-agent anti-tumor efficacy in the highly immunosuppressive B16F10 melanoma mouse model;
Synergy with a subtherapeutic dose of anti-PD1 in the MC38 colorectal cancer mouse model;
And a favorable safety profile.
A copy of the poster titled "RIDE-001: A well-tolerated innate immunotherapy to treat cancer by targeting and reprogramming bone marrow progenitor cells" (abstract number 1178) is available on the company’s website.

(Press release, Trained Therapeutix Discovery, NOV 7, 2025, View Source [SID1234660997])

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025

On November 7, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported that the Company is presenting evidence of strong immune system engagement and anti-cancer activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40 th Anniversary Annual Meeting, to be held November 7-9, 2025, in National Harbor, MD.

Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance
Abstract Number: 353
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
Date: Friday, November. 7, 2025
Time : 12:15-1:45 PM, and 5:35-7 PM ET

"We are thrilled with the comprehensive, powerful, and long-lasting immune activation demonstrated by Bria-OTS+ in our preclinical studies, which we believe will translate into meaningful anti-cancer immune responses in the clinic," stated Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer. "By training both the innate and adaptive arms of the immune system, Bria-OTS+ represents an important step toward developing more durable and broadly effective cancer immunotherapies."

"These findings add to the growing body of evidence supporting our Bria-OTS+ platform’s unique mechanism of action for novel personalized cancer immunotherapies. We look forward to confirming these encouraging preclinical results in planned clinical trials of Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer," commented Dr. William V. Williams, BriaCell’s President and CEO.

Summary of Preclinical Findings

Bria-OTS+ Fast Acting and Potent Anti-Cancer Immune System Activation :
Bria-BRES+ and Bria-PROS+ rapidly activated key components of the immune system in preclinical models. The platform induced coordinated innate and adaptive immune responses, training the immune system to kill cancer cells. These findings are consistent with strong anti-tumor immune activity and support its promise as BriaCell’s next generation cancer immunotherapy platform.

Bria-OTS+ Long Lasting Anti-Cancer Response :
Both Bria-BRES+ and Bria-PROS+ produced sustained, and durable anti-cancer immune responses that may translate into prolonged clinical benefit for patients treated with the Bria-OTS+ platform of whole cell immunotherapies.

Bria-OTS+: Broad Applicability :
Positive results with lead candidates Bria-BRES+ and Bria-PROS+ reinforce the broad applicability of the Bria-OTS+ platform and support possible expansion into other solid tumor indications. These data highlight the platform’s capacity to generate broad and potent immune responses against multiple tumor types that share key immune-recognition features.

(Press release, BriaCell Therapeutics, NOV 7, 2025, View Source [SID1234660840])

TwoStep Therapeutics to Present at the 2025 SITC Annual Meeting

On November 7, 2025 TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate therapies for solid tumors, reported it will be presenting a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 40th Annual Meeting, being held November 7–9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD.

Poster Presentation:
Title: A multi-integrin targeting peptide-drug conjugate induces durable tumor regression with a strong preclinical safety profile
Date and Time: Saturday, November 8, 2025
Abstract Number: 948
Authors: Yash Agarwal, Caleb Perez, Joy Geallis, Caitlyn Miller
Recognized among the Top 15% of accepted abstracts.

(Press release, TwoStep Therapeutics, NOV 7, 2025, View Source [SID1234659661])